Data from the IMPRESS study 2,3
A retrospective, observational, multicentre study including 145 patients with HE from 11 UK NHS centres. Conducted from Aug 2014 to Jun 2015.
AIM: To compare resource use in the 6 and 12 months before and after rifaximin-α initiation in UK patients with HE.
This study was sponsored by Norgine.
AIM: To compare resource use in the 6 and 12 months before and after rifaximin-α initiation in UK patients with HE.
This study was sponsored by Norgine.
Critical care bed days per patient
3
All-cause admissions
In UK clinical practice, treatment with rifaximin‑α was associated with significant reductions in critical care bed occupancy at 6 and 12 months.
UK/XIF5/0719/0523 DOP: October 2019